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Abstract
Rationale—Assays of schedule-controlled responding can be used to characterize the
pharmacology of benzodiazepines and other GABAA receptor modulators, and are sensitive to
changes in drug effects that are related to physical dependence.
Objective—The present study used this approach to investigate the role of GABAA receptor
subtypes in mediating dependence-like effects following benzodiazepine administration.
Methods—Squirrel monkeys (n=6) were trained on a fixed-ratio schedule of food reinforcement.
Initially, the response rate-decreasing effects of chlordiazepoxide (0.1–10 mg/kg; nonselective
GABAA receptor agonist), zolpidem (0.032–1.0 mg/kg; α1 subunit-containing GABAA subtype-
preferring agonist) and HZ-166 (0.1–10 mg/kg; functionally selective α2 and α3 subunit-
containing GABAA receptor agonist) were assessed. Next, acute dependence-like effects
following single injections of chlordiazepoxide, zolpidem and HZ-166 were assessed with
flumazenil (0.1–3.2 mg/kg; nonselective GABAA receptor antagonist). Finally, acute dependence-
like effects following zolpidem administration were assessed with βCCt and 3-PBC (0.1–3.2 mg/
kg and 0.32–10 mg/kg, respectively; α1 subunit-containing GABAA receptor antagonists).
Results—Chlordiazepoxide, zolpidem and HZ-166 produced dose- and time-dependent
decreases in response rates, whereas flumazenil, βCCt and 3-PBC were ineffective. After the drug
effects waned, flumazenil produced dose-dependent decreases in response rates following
administration of 10 mg/kg chlordiazepoxide and 1.0 mg/kg zolpidem, but not following any dose
of HZ-166. Further, both βCCt and 3-PBC produced dose-dependent decreases in response rates
when administered after 1.0 mg/kg zolpidem.
Conclusions—These data raise the possibility that α1 subunit-containing GABAA receptors
play a major role in physical dependence-related behaviors following a single injection of a
benzodiazepine.
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INTRODUCTION
The γ-aminobutyric acid type A (GABAA) receptors are the primary sites of action for
benzodiazepines and related drugs used to treat anxiety and sleep disorders. The therapeutic
use of benzodiazepine-type drugs for the treatment of these disorders is constrained,
however, by other characteristic effects such as daytime drowsiness, motor impairments and
reinforcing effects that are thought to contribute to their abuse (Griffiths and Weerts, 1997;
Licata and Rowlett, 2008). In addition, benzodiazepines have also the propensity to produce
physical dependence which can be observed following not only chronic treatment but may
also manifest following a single drug administration (e.g. Lukas and Griffiths, 1984;
Spealman, 1986; Bronson, 1994).
Benzodiazepines bind to a specific site on GABAA receptors where they induce a
conformational change, leading to an allosteric enhancement in the ability of GABA to
increase chloride conductance. Over the past two decades, research has revealed the
existence of multiple subtypes of the GABAA receptor (e.g., Pritchett et al., 1989; Rudolph
et al., 2001; Olsen and Sieghart, 2008); and subsequent reports have provided evidence to
support the notion that the diverse behavioral effects of benzodiazepine-type drugs may
reflect their action at these different subtypes (Rudolph et al., 1999; McKernan et al., 2000;
Löw et al., 2000; Rowlett et al., 2005). These observations raise the possibility for a
pharmacological dissociation between the clinically advantageous effects and unwanted
side-effects of these compounds.
GABAA receptors in the central nervous system are pentamers constituted from structurally
distinct proteins, with each protein family consisting of different subunits (for review, see
Rudolph et al., 2001). The majority of GABAA receptors are composed of α, β and γ
subunits; and benzodiazepines bind to a site on the native GABAA receptor that is located at
the interface of the γ2 subunit and one of the α1, α2, α3 or α5 subunits. Studies in rodent
models have suggested a differential anatomical distribution among these GABAA subunit-
containing receptors. In this regard, GABAA receptors containing α1 subunits (α1GABAA
receptors) are ubiquitously located, and have been implicated in the sedative, operant rate-
reducing and reinforcing effects of benzodiazepines (Rudolph et al., 1999; Licata et al.,
2005; Fischer et al., 2010; Tan et al., 2010). In contrast, GABAA receptors containing α2
and α3 subunits (α2GABAA and α3GABAA receptors, respectively) are anatomically
distributed in the cortex, limbic system and spinal cord, and have been associated with the
anxiolytic and antihyperalgesic effects of benzodiazepines (McKernan et al., 2000; Löw et
al., 2000; Rowlett et al., 2005, Fischer et al., 2010; Knabl et al., 2008). Finally, GABAA
receptors containing α5 subunits (α5GABAA receptors) are a relatively minor population
expressed primarily within the hippocampus and are thought to play a role in certain
memory processes associated with benzodiazepines (Collinson et al., 2002; Crestani et al.,
2002; Atack et al., 2006).
The contribution that the different GABAA receptor subtypes have in benzodiazepine-
induced physical dependence is less clear. Limited data is available to delineate a role of the
GABAA receptor subtypes following repeated administration (e.g. Mirza and Nielsen,
2006); and the role of these receptors in acute physical dependence following a single
administration has yet to be addressed. In the former study, the GABAA receptor inverse
agonist FG-7142 precipitated withdrawal in mice following chronic administration of a
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series of conventional benzodiazepines, but failed to do so following chronic administration
of the α1GABAA receptor-sparing compounds SL651498 and L-838,417 (Mirza and
Nielsen, 2006). Together, these findings raise the possibility that α1GABAA receptors may
play a key role in benzodiazepine-induced physical dependence following chronic treatment.
The current study was designed to assess further the physical dependence-like effects that
follow benzodiazepine administration, particularly the role that GABAA receptor subtypes
play in dependence following a single drug administration. Towards this end, squirrel
monkeys were trained in an operant conditioning procedure in which behavior was
maintained by the presentation of food pellets. This approach was chosen as it is an
established method commonly used to quantify changes in behavior related to dependence
(e.g. Holtzman and Villarreal, 1973; McMahon and France, 2002), and is a particularly
sensitive measure of acute dependence (e.g. Spealman 1986, Bronson, 1994). Moreover, this
approach has been shown to be advantageous in delineating receptor subtype mechanisms in
other systems (e.g., opioid receptor subtypes, Adams and Holtzman 1990). Initial studies
established a model of physical dependence-like effects as evident from an increased
potency of the nonselective GABAA receptor antagonist flumazenil following a single
injection of the nonselective benzodiazepine chlordiazepoxide. Subsequent studies assessed
the role of the GABAA receptor subtypes that mediate this effect by administering the
α1GABAA-preferring agonist zolpidem and the α2GABAA/α3GABAA agonist HZ-166 as
pretreatment. Finally, the role of α1GABAA receptors was examined further by assessing




Six adult squirrel monkeys (Saimiri sciureus) were maintained on a 12-hr lights-on/12-hr
lights-off cycle (lights on at 7:00 AM). Water was available continuously in the home cage
and food was available in the home cage after the session. Monkeys were prepared with a
chronic indwelling polyvinyl chloride catheter according to previously described procedures
(Platt et al., 2011). In brief, under isoflurane anesthesia and aseptic conditions, one end of a
catheter was passed to the level of the right atrium by way of a femoral or jugular vein. The
distal end of the catheter was passed subcutaneously and exited the skin in the midscapular
region. Catheters were flushed daily with heparinized 0.9% saline solution and sealed with
stainless-steel obturators when not in use. Monkeys wore nylon-mesh jackets (Lomir
Biomedical, Toronto, Canada) at all times to protect the catheter.
Squirrel monkeys weighed between 0.7 and 1.2 kg throughout the study. Two of the six
monkeys were experimentally naïve, two monkeys had previous experience discriminating
methamphetamine from vehicle, one monkey had previous experience discriminating a
benzodiazepine from vehicle and one monkey had previous experience self-administrating
intravenous cocaine. Animals in this study were maintained in accordance with the
guidelines of the Committee on Animals of Harvard Medical School and the Guide for Care
and Use of Laboratory Animals (8th edition, 2011). Research protocols were approved by
the Harvard Medical School Institutional Animal Care and Use Committee.
Operant conditioning behavior
Rates of responding were assessed in an experimental operant chamber during daily
sessions, typically 5 days each week (Monday through Friday). Monkeys sat in a Plexiglas
chair facing a panel equipped with stimulus lights, a response lever and a food pellet
receptacle (MED Associates, St. Albans, VT). The operant conditioning chamber was
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controlled by a MED-PC interface and an IBM-compatible computer programmed with
MED Associates software (MED Associates).
Monkeys were trained under a multiple-cycle procedure consisting of a 7-min pretreatment
period followed by a 3-min response period. During the pretreatment period, stimulus lights
were not illuminated and responding had no scheduled consequences. During the response
period, the stimulus lights were illuminated and monkeys could obtain up to 10 food pellets
(Bioserve, Frenchtown, NJ) under a fixed-ratio 10 schedule of food presentation. If all 10
reinforcers were earned before 3-min had elapsed, the light was turned off and responding
had no scheduled consequences for the remainder of the response period. Training sessions
consisted of five consecutive cycles, and testing began once response rates were stable
throughout the session.
Test sessions were conducted in lieu of training sessions once or twice per week if
responding was stable throughout the five preceding training sessions, defined as the
average rates of responding for each cycle not varying by more than 20%, with no upward or
downward trends. Test sessions were identical to training sessions, except that cumulative
doses of drug were administered i.v. 2-min into the pretreatment period of each cycle (i.e.,
5-min pretreatment time; 10-min inter-injection interval), increasing in one-half log unit
increments. The first series of tests assessed the cumulative dose-effect curves and time-
course of chlordiazepoxide, zolpidem or HZ-166 alone. Next, doses of chlordiazepoxide,
zolpidem or HZ-166 were given as a pre-session pretreatment, followed by dose-effect
curves for flumazenil, βCCT and 3-PBC via cumulative dosing. During test sessions in
which a pretreatment was administered, the pretreatment time was based upon the duration
of action of each compound.
Drugs
Chlordiazepoxide hydrochloride and flumazenil were purchased from Sigma-Aldrich (St.
Louis, MO) and zolpidem L-tartaric acid salt was a gift from Dr. K. Fang (Sepracor, Inc.;
Marlborough, MA) and dissolved in 50% propylene glycol, 50% sterile water. HZ-166 (8-
ethynyl-6-(2'-pyridine)-4H-2,5,10b-triaza-benzo[e]azulene-3-carboxylic acid ethyl ester),
βCCT (β-carboline-3-carboxylate-tert-butyl ester) and 3-PBC (3-propoxy-β-carboline
hydrochloride) were synthesized at the Department of Chemistry and Biochemistry,
University of Wisconsin-Milwaukee and dissolved in 20% ethanol, 60% propylene glycol
and 20% sterile water. Pretreatment doses of chlordiazepoxide (1.0–10 mg/kg), zolpidem
(0.1–1.0 mg/kg) and HZ-166 (1.0–10 mg/kg) were chosen based upon the preliminary dose-
effect curves as determined in the present or previous studies (Spealman, 1986; McMahon
and France 2002; Fischer et al., 2010).
Data analysis
The number of responses on the lever per second were recorded and expressed as a
percentage of control responding using the average rate of responding from the previous day
as the control value (average of five cycles) for individual animals. Data are expressed
graphically as the mean (± the standard error of the mean, SEM) percent control response
rate from the group. Rates of responding during time-course experiments were considered to
have returned to baseline if they were within 10% of the control baseline response rates (i.e.
a minimum of 90% control). To compare changes in the behavioral effects following
antagonist (flumazenil, βCCT and 3-PBC) administration, a two way analysis of variance
(ANOVA) was conducted. Additional Bonferroni t-tests were also conducted to compare
individual doses versus the antagonist alone control. For all tests, the level of statistical
significance was set at p < 0.05. If significant antagonist-induced rate decreasing effects
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were detected, potency values (dose reducing responding to 75% of control, ED75) were
calculated by log-linear regression from the descending limb of the group dose-effect curve.
RESULTS
Figure 1 (top) shows the rate-decreasing effects of chlordiazepoxide, zolpidem and HZ-166.
Chlordiazepoxide, zolpidem and HZ-166 produced statistically significant decreases in
schedule-controlled responding across the dose ranges studied, resulting in ED75 values
(mg/kg, i.v.) of 3.5 (±0.42 SEM), 0.21 (±0.044 SEM) and 3.2 (±1.5 SEM), respectively.
When assessed over time (Figure 1, bottom), operant responding returned to baseline values
(i.e., ≥ 90% control) at 100 min following administration of zolpidem, 300 min following
administration of HZ-166 and 1440 min following administration of chlordiazepoxide, and
these values were used as pretreatment times during subsequent experiments.
Figure 2 (top) shows the rate-decreasing effects of flumazenil alone and following the 1440
min pretreatment with chlordiazepoxide. Flumazenil was without effect across the dose
range tested. Flumazenil did, however, suppress schedule-controlled responding in a dose-
dependent manner following chlordiazepoxide pretreatment [F(3,36) = 17; p < 0.001]. In
this regard, flumazenil did not decrease rates of responding following pretreatment doses of
1.0 mg/kg chlordiazepoxide and 3.2 mg/kg chlordiazepoxide, whereas flumazenil did
decrease rates of responding following a pretreatment dose of 10 mg/kg chlordiazepoxide,
resulting in a flumazenil ED75 value of 0.074 (± 0.057 SEM). Bonferroni t-tests revealed
that flumazenil doses of 0.32–3.2 mg/kg suppressed response rates following pretreatment of
10 mg/kg chlordiazepoxide.
Figure 2 (middle) also shows the rate-decreasing effects of flumazenil alone and following
pretreatment with zolpidem (100 min pretreatment). Flumazenil suppressed schedule-
controlled responding in a dose-dependent manner following zolpidem pretreatment
[F(3,28) = 12; p < 0.001]. Here, flumazenil did not decrease rates of responding following
0.1 mg/kg and 0.32 mg/kg zolpidem, but significant decreases in response rates were
observed following 1.0 mg/kg zolpidem, resulting in an ED75 value of 0.34 (±0.12 SEM).
Bonferroni t-tests revealed that flumazenil doses of 1.0 mg/kg and 3.2 mg/kg decreased
response rates following this dose of zolpidem. Also shown in Figure 2 (bottom) are the
effects of flumazenil following 300-min pretreatment with HZ-166 on operant behavior. In
contrast to zolpidem, pretreatment with HZ-166 failed to affect the flumazenil dose response
curve across all doses tested, and an ED75 value could not be calculated.
Figure 3 shows the rate-decreasing effects of βCCT (top) and 3-PBC (bottom) alone and
following pretreatment with zolpidem. βCCT and 3-PBC were ineffective when
administered alone. Following zolpidem pretreatment, however, both βCCT [F(3,32) = 5.9;
p = 0.002] and 3-PBC [F(3,32) = 6.1; p = 0.002] were effective, depending on the
pretreatment dose. In this regard, βCCT and 3-PBC did not decrease rates of responding
following pretreatment doses of 0.1 mg/kg and 0.32 mg/kg zolpidem, whereas both GABAA
receptor antagonsits did decrease rates of responding following a pretreatment dose of 1.0
mg/kg zolpidem. The resulting ED75 values for βCCT and 3-PBC were 0.16 (±0.060 SEM)
and 1.3 (±0.30 SEM), respectively. Bonferroni t-tests revealed that the βCCT dose of 1.0
mg/kg decreased response rates following 1.0 mg/kg zolpidem. Further, Bonferroni t-tests
showed that the 3-PBC doses of 3.2 and 10 mg/kg decreased response rates following 1.0
mg/kg zolpidem.
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Conventional benzodiazepines bind non-selectively across α1GABAA, α2GABAA,
α3GABAA and α5GABAA receptors; however, the role of these receptor subtypes in
benzodiazepine-induced physical dependence is understood poorly. In the present study, we
used an assay of schedule-controlled responding to characterize the role of α1GABAA,
α2GABAA and α3GABAA receptors on an endpoint related to acute physical dependence.
Initial studies demonstrated that chlordiazepoxide, zolpidem and HZ-166 produced dose-
dependent decreases in rates of responding, whereas the GABAA receptor antagonists
flumazenil, βCCT and 3-PBC were ineffective over the dose ranges tested. Flumazenil
suppressed rates of responding following pretreatment of the non-selective benzodiazepine
chlordiazepoxide, as well as pretreatment with the α1GABAA-preferring agonist zolpidem.
In contrast, flumazenil did not suppress rates of responding following pretreatment with the
α2GABAA/α3GABAA agonist HZ-166. Further, the α1GABAA-preferring antagonists
βCCT and 3-PBC decreased response rates following zolpidem pretreatment. Together,
these findings raise the possibility that α1GABAA receptors, but not α2GABAA or
α3GABAA receptors, play an important role in behaviors that are related to the initiation of
physical dependence following conventional benzodiazepine administration. Moreover,
these data suggest that the receptor profile that underpins benzodiazepine-induced physical
dependence may be different from receptors that mediate other behavioral effects, including
antihyperalgesia and anxiolysis.
The positive GABAA receptor modulators that decreased responding did so with a potency
ranking of zolpidem > chlordiazepoxide = HZ-166, whereas the GABAA receptor
antagonists lacked effects. The finding that zolpidem and chlordiazepoxide reduced rates of
responding is consistent with a number of studies demonstrating that various positive
GABAA modulators with activity at α1GABAA receptors decrease responding maintained
under a variety of operant schedules (e.g., Paronis and Bergman 1999; Vanover et al., 1999;
Rowlett et al., 2005; Fischer et al., 2010). Further, flumazenil, βCCT and 3-PBC,
compounds that do not substantially modify GABA-mediated chloride flux at α1GABAA
receptors (Smith et al., 2001; Harvey et al., 2002), failed to alter rates of responding,
consistent with previous studies (McMahon and France, 2002). In contrast, the observation
that HZ-166 reduced rates of responding, albeit not completely, was unexpected considering
the relatively low intrinsic efficacy of HZ-166 at α1GABAA receptors, and contrasts
previous observations that this and related compounds do not alter response rates under a
similar schedule following i.v. administration in rhesus monkeys (Fischer et al., 2010). The
reasons for this discrepancy are unclear. One possibility is that weak activity at α1GABAA
receptors is sufficient for rate-reducing effects in squirrel monkeys; however this is unlikely
since SH-053-2’F-R-CH3, a compound with a similar pharmacological profile to that of
HZ-166 at α1GABAA receptors (Fischer et al., 2010; Savic et al., 2010) does not produce
rate decreasing effects in this species across a similar dose range (unpublished). Therefore,
the results from the present study suggest that activation of α2GABAA and α3GABAA
receptors is sufficient for modest behavioral disruption in squirrel monkeys under certain
conditions.
The finding that flumazenil suppressed schedule controlled responding following
pretreatment with chlordiazepoxide is consistent with the findings described by Spealman
(1986). In this study, flumazenil (i.e. Ro 15-1788) did not produce disruptions in behavior
when administered alone, but did so following administration with the benzodiazepines
chlordiazepoxide and diazepam, as well as the diazepam metabolite N-desmethyldiazepam
on responding maintained under both fixed ratio and fixed interval schedules of
reinforcement. This alteration of flumazenil potency has been interpreted as a measure of
physical dependence, as the rate-decreasing effects of flumazenil are most likely due to the
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precipitation of withdrawal (Holtzman and Villarreal, 1973; Lukas and Griffiths, 1982;
Gerak and France, 1997; McMahon and France, 2002).
The main purpose of the present study was to test the hypothesis that acute benzodiazepine-
induced physical dependence-like effects may be mediated by specific α subunit-containing
GABAA receptors. In order to explore GABAA receptor mechanisms in this effect, initial
studies examined the rate-decreasing effects of flumazenil following pretreatment with
zolpidem and HZ-166. Here, flumazenil decreased response rates following pretreatment
with zolpidem in a similar manner to that seen after chlordiazepoxide pretreatment. This
observation raises the possibility that α1GABAA receptors may play a substantial role in
benzodiazepine-induced physical dependence. In contrast, flumazenil did not decrease
response rates following pretreatment with doses as high as 10 mg/kg HZ-166. It is
important to note that the doses of HZ-166 administered as pretreatment were behaviorally
effective in the initial dose- and time-effect determinations. Therefore, the lack of effect
from this drug in inducing a dependence-like state is likely not due to insufficient
modulation of GABAA-mediated chloride influx at α2GABAA and/or α3GABAA receptors.
The finding that flumazenil suppressed schedule-controlled responding following zolpidem
pretreatment supports further the hypothesis that α1GABAA receptors mediate acute
dependence-like effects. However, although zolpidem has preferential (~10-fold) selectivity
for α1GABAA receptors relative to α2GABAA and α3GABAA receptors, it does activate
the latter subtypes at higher doses. Therefore, to explore further the role of α1GABAA
receptors on this endpoint, we sought to characterize the enhanced effectiveness of two
α1GABAA-preferring antagonists, βCCT and 3-PBC, following zolpidem administration.
βCCT and 3-PBC have an approximately 10 to 100-fold greater affinity for α1GABAA
receptors relative to α2GABAA and α3GABAA and α5GABAA receptors (Harvey et al.,
2002). Although βCCT and 3-PBC were ineffective when administered alone, both drugs
decreased rates of operant responding following zolpidem pretreatment. Considering the
affinity of these compounds for α1GABAA receptors, this observation provides additional
support for a role of this receptor subtype in zolpidem-induced physical dependence, and in
turn provides additional evidence to suggest that α1GABAA receptors may play an
important role in benzodiazepine-induced physical dependence.
In consideration of evidence suggesting that physical dependence is an α1GABAA receptor-
mediated phenomenon, it is perhaps surprising that initial reports following the introduction
of zolpidem suggested that it had a reduced propensity to produce dependence. These initial
reports demonstrated a lack of withdrawal-like behaviors following long-term administration
and drug discontinuation (Perrault et al., 1992; Elliot and White 2000). Subsequently, these
reports were used to suggest that zolpidem was a safer compound relative to conventional
benzodiazepines (e.g. Holm and Goa, 2000). However, these reports have been contrasted
by other studies in which zolpidem-induced physical dependence was apparent (e.g.
Griffiths et al., 1992; Weerts and Griffiths, 1998; Kliethermes et al., 2004), and is in
concordance with numerous clinical accounts of zolpidem dependence (cf. Victorri-Vigneau
et al., 2007). The extent to which these differences across studies reflect variables such as
species and/or methodology used to demonstrate dependence remains to be determined.
Regardless, our findings add to the growing empirical support of the presence of physical
dependence-like effects associated with zolpidem administration.
Taken together with previously described experiments, the data from the present study
provides additional evidence that the behavioral effects of benzodiazepines are mediated by
different α subunit-containing GABAA receptor subtypes. Our findings implicate
α1GABAA receptors in benzodiazepine-induced physical dependence-like effects, and
suggest further that the receptor mechanisms that underpin physical dependence may be
Fischer et al. Page 7













different than those that mediate anxiolysis and antihyperalgesia (α2GABAA and
α3GABAA receptor subtypes). Further, our findings suggest that it may be difficult to
dissociate α1GABAA receptor-mediated therapeutic effects (e.g. the sedative effects found
in sleep aids) from dependence-like effects. These hypotheses should provide an important
framework for studying the role of different GABAA receptor subtypes in the abuse-related
effects of benzodiazepine-type drugs, which in turn should help guide both the current
clinical use of benzodiazepines as well as the development of improved therapeutic agents
for treating anxiety- and pain-related disorders.
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Dose-effect curves (top panel) and time-course (bottom panel) of the positive GABAA
receptor modulators chlordiazepoxide, zolpidem and HZ-166 on schedule-controlled
responding. Abscissae, dose of drug in milligrams per kilogram or time after drug
administration. Ordinate, mean (±SEM) rate of responding as percentage of control. Points
above “V’ indicate average rates of responding (±SEM) following vehicle administration.
Asterisks represent significant differences relative to vehicle (Bonferroni t-tests, p<0.05).
Time-course data were determined following the highest dose tested for each drug (10 mg/
kg chlordiazepoxide, 1 mg/kg zolpidem and 10 mg/kg HZ-166).
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Effects of flumazenil on schedule-controlled responding, either alone or following
pretreatment with chlordiazepoxide (top), zolpidem (middle) or HZ-166 (bottom).
Pretreatment times for each GABAA receptor agonist were 1440 min, 100 min or 300 min,
respectively. Abscissa, dose of flumazenil in milligrams per kilogram. Ordinate, mean
(±SEM) response rate as percentage of control. Points above “V” indicate mean (±SEM)
rates of responding following vehicle administration, either alone or following GABAA
receptor agonist pretreatment. Asterisks represent significant differences relative to vehicle
(Bonferroni t-tests, p<0.05).
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Effects of βCCT (top panel) and 3-PBC (bottom panel) on schedule-controlled responding,
either alone or following pretreatment with zolpidem. The pretreatment time for zolpidem
prior to both GABAA receptor antagonists was 100 min. Abscissae, dose of drug in
milligrams per kilogram. Ordinate, mean (±SEM) response rate as percentage of control.
Points above “V” indicate mean (±SEM) rates of responding following vehicle
administration, either alone or following zolpidem pretreatment. Asterisks represent
significant differences relative to vehicle (Bonferroni t-tests, p<0.05).
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